Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
about
Eosinophilia in Hematologic DisordersCIViC databaseInflammatory myofibroblastic tumors harbor multiple potentially actionable kinase fusionsHypereosinophilic Syndrome With Eosinophilic Gastritis.Hypereosinophilic syndrome and clonal eosinophilia: point-of-care diagnostic algorithm and treatment update.Patients with myeloid malignancies bearing PDGFRB fusion genes achieve durable long-term remissions with imatinib.Screening for diverse PDGFRA or PDGFRB fusion genes is facilitated by generic quantitative reverse transcriptase polymerase chain reaction analysis.A phase 1 study of imatinib for corticosteroid-dependent/refractory chronic graft-versus-host disease: response does not correlate with anti-PDGFRA antibodies.FLT3 mutations confer enhanced proliferation and survival properties to multipotent progenitors in a murine model of chronic myelomonocytic leukemia.Omics Screening for Pharmaceutical Efficacy and Safety in Clinical PracticeImatinib mesylate in the treatment of hematologic malignancies.Fibroblast growth factor receptor and platelet-derived growth factor receptor abnormalities in eosinophilic myeloproliferative disorders.Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis.Long-term outcomes of imatinib in patients with FIP1L1/ PDGFRA associated chronic eosinophilic leukemia: experience of a single center in China.Recent breakthroughs in the understanding and management of chronic eosinophilic leukemia.World Health Organization-defined eosinophilic disorders: 2011 update on diagnosis, risk stratification, and management.Tyrosine kinase gene fusions in cancer: translating mechanisms into targeted therapies.World Health Organization-defined eosinophilic disorders: 2012 update on diagnosis, risk stratification, and management.Review of current classification, molecular alterations, and tyrosine kinase inhibitor therapies in myeloproliferative disorders with hypereosinophilia.World Health Organization-defined eosinophilic disorders: 2014 update on diagnosis, risk stratification, and management.Toward a therapeutic reduction of imatinib refractory myeloproliferative neoplasm-initiating cells.Multiple oligomerization domains of KANK1-PDGFRβ are required for JAK2-independent hematopoietic cell proliferation and signaling via STAT5 and ERK.Discovery of imatinib-responsive FIP1L1-PDGFRA mutation during refractory acute myeloid leukemia transformation of chronic myelomonocytic leukemia.Myeloid Neoplasms with t(5;12) and ETV6-ACSL6 Gene Fusion, Potential Mimickers of Myeloid Neoplasm with PDGFRB Rearrangement: Case Report with Imatinib Therapy and Review of the Literature.Novel t(5;19) Translocation in a Patient with PDGFRB Associated Chronic Leukemia: Implications for Treatment Strategy.PDGFRᵝ-Rearranged Myeloid Neoplasm with Marked Eosinophilia in a 37-Year-Old Man; And a Literature Review.PDGFRA alterations in cancer: characterization of a gain-of-function V536E transmembrane mutant as well as loss-of-function and passenger mutations.Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204-PDGFRB fusion in a patient with recurrent T-ALL and an associated myeloproliferative neoplasm.Imatinib in myeloid/lymphoid neoplasms with eosinophilia and rearrangement of PDGFRB in chronic or blast phase.Platelet-derived growth factors and their receptors in normal and malignant hematopoiesisMultiple MYO18A-PDGFRB fusion transcripts in a myeloproliferative neoplasm patient with t(5;17)(q32;q11).Successful treatment with low-dose imatinib mesylate of therapy-related myeloid neoplasm harboring TEL-PDGFRB in a patient with acute promyelocytic leukemia.Myeloid and lymphoid neoplasms with eosinophilia and abnormalities of PDGFRA, PDGFRB or FGFR1.PDGFRB mutants found in patients with familial infantile myofibromatosis or overgrowth syndrome are oncogenic and sensitive to imatinib.KANK1, a candidate tumor suppressor gene, is fused to PDGFRB in an imatinib-responsive myeloid neoplasm with severe thrombocythemia.Long-term follow-up of treatment with imatinib in eosinophilia-associated myeloid/lymphoid neoplasms with PDGFR rearrangements in blast phase.Molecular diagnosis and targeted therapy of a pediatric chronic eosinophilic leukemia patient carrying TPM3-PDGFRB fusion.World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.Marked response to imatinib mesylate in a patient with platelet-derived growth factor receptor beta-associated acute myeloid leukemia.Fusion of PDGFRB to MPRIP, CPSF6, and GOLGB1 in three patients with eosinophilia-associated myeloproliferative neoplasms.
P2860
Q26799611-EDC68758-A098-42DD-B22C-885039872AF3Q27612411-C0DD3B28-214F-4BCB-8C2F-D6D5B4279DDDQ27853012-9D25D298-5960-4BB4-A46E-FD22FD55B9DDQ33606709-B5B4CDA2-CE69-487C-9DF9-1F9A20CFDB8AQ33620407-D6BFEC26-5AD7-424B-82C5-434C0115FD75Q33718814-365EB3F5-1DC3-4557-80D0-C54558950941Q33829070-317B867B-E555-4BFD-BC49-C8C34D62CA31Q35865095-A49A29C7-F8BE-4C50-91C7-7B50C53AB769Q36183556-19F043EC-C877-4070-8670-704955C2719DQ36477760-15457CDA-665F-43CD-BE70-D7EC4A203F8AQ36960525-9307D136-D514-44BE-BFEC-4AA9A4068722Q37195685-89A8D96E-96E3-4725-92FB-BA2C889D8FB3Q37247964-35E37943-D382-43D1-926E-686F86AE29D6Q37362888-C8A64B79-9A2D-4204-8AA5-9F2EAD8B229DQ37598944-5210D934-3D2E-4C08-BBAC-B02DBC18A8FAQ37901437-E5A344C0-4003-4C93-BA3C-224CB6E13BC0Q37919976-89BDDE52-0D14-455E-A892-DD87AC8CCAA8Q38038509-757D6013-4147-4524-AF86-BAFADDD0FDE3Q38131481-B1B4A825-BBED-49A5-9838-40E886688823Q38191834-9C529695-6517-4260-8B22-BDA76D7DF1A5Q38311168-C856AC5F-52DE-4F01-9119-6AECE1771723Q38620874-FB6006C4-A360-4036-9DFA-5066EFEA00A4Q38868681-3CDB9E19-2943-420F-B8F9-2BB3B0E5F229Q38982112-6157574C-C1F5-422C-BA6C-06DC66988FADQ39111592-FA332438-DF80-491D-A092-24A307D80F80Q39139762-F55645B3-D18A-419F-A0A2-448564A84756Q39141642-5C12B599-2443-4CE9-8F61-CD9149FA0784Q39469909-12CC7C1E-B7D2-495C-A898-7C167114E43BQ40115606-5F95E969-559C-484B-A3C3-D2783328A28FQ42126072-7BEC5A81-59CE-4DE5-87D8-FC29C81482D4Q42269940-652093F6-6BFD-4561-BEE2-27B0CFCD928EQ42434746-880E3804-C3E6-4AF0-AB7B-F9028016A827Q42793025-4E3A16D3-41A9-4F46-B4FB-E06689FF579AQ42819833-EF6FB17F-F9D2-45F9-9EFA-55014D8EF68FQ43158404-28A46B80-78A5-413B-A8BE-611BD2E69D49Q44652111-9810EFCC-6650-46A1-B76E-1332A0F42B27Q45371820-E7463BED-BE07-4F44-B473-351FA9AA950BQ46026437-A6E10D02-6E7C-4F2A-AEB9-1F3A323972C0Q51246186-8738310D-A32A-4B36-AADB-21964499FFFDQ53350377-5E1019CA-3F54-4933-B4EF-D63FDB0B49B9
P2860
Durable responses to imatinib in patients with PDGFRB fusion gene-positive and BCR-ABL-negative chronic myeloproliferative disorders.
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Durable responses to imatinib ...... myeloproliferative disorders.
@ast
Durable responses to imatinib ...... myeloproliferative disorders.
@en
Durable responses to imatinib ...... myeloproliferative disorders.
@nl
type
label
Durable responses to imatinib ...... myeloproliferative disorders.
@ast
Durable responses to imatinib ...... myeloproliferative disorders.
@en
Durable responses to imatinib ...... myeloproliferative disorders.
@nl
prefLabel
Durable responses to imatinib ...... myeloproliferative disorders.
@ast
Durable responses to imatinib ...... myeloproliferative disorders.
@en
Durable responses to imatinib ...... myeloproliferative disorders.
@nl
P2093
P3181
P1433
P1476
Durable responses to imatinib ...... myeloproliferative disorders.
@en
P2093
Alastair Stark
Andrew Chase
Claire Curtis
Francis Grand
Francois X Mahon
Francoise Huguet
George Hughes
Giorgio Massimini
Graeme Smith
Grant A McArthur
P3181
P356
10.1182/BLOOD-2006-05-024828
P407
P577
2007-01-01T00:00:00Z